TTP 814

Drug Profile

TTP 814

Alternative Names: TTP814

Latest Information Update: 22 Sep 2015

Price : $50

At a glance

  • Originator TransTech Pharma
  • Developer vTv Therapeutics
  • Class Antihyperglycaemics
  • Mechanism of Action Protein-tyrosine-phosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 22 Sep 2015 Discontinued - Phase-I/II for Type-2 diabetes mellitus in USA (PO)
  • 11 Jun 2010 Phase-I/II clinical trials in Type-2 diabetes mellitus in USA (PO)
  • 27 Jul 2004 Preclinical trials in Type-2 diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top